GlassScriptPhysician profile
Frederick M Detorres
NPI 1518023480
$23,901.85
in general payments reported to CMS, 2019-2025
29 companies · $951 in 2025
The $951 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $7,416 · 2021: $11K · 2022: $1,013 · 2023: $1,009 · 2024: $1,348 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,251 · Education: $57.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.47 |
| Education | $57.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18,326.33 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,266.57 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Novartis Pharmaceuticals Corporation | $655.98 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.66 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $438.89 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $402.73 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Csl Behring | $360.34 | 2019-2025 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $343.65 | 2021-2025 | Eohilia, Takhzyro, Cuvitru |
| Genentech USA, INC. | $248.77 | 2021-2025 | Xolair |
| Amgen INC. | $200.80 | 2021-2025 | Tezspire |
| Pharming Healthcare, INC. | $143.53 | 2021-2025 | Ruconest |
| Pfizer INC. | $127.68 | 2021-2023 | |
| Kaleo, INC. | $106.78 | 2019-2023 | Auvi-Q |
| Abbvie INC. | $103.29 | 2021-2023 | Rinvoq |
| Genzyme Corporation | $99.64 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $96.28 | 2020-2021 | |
| Biocryst US Sales Co., LLC | $79.51 | 2021-2024 | Orladeyo |
| Blueprint Medicines Corporation | $72.40 | 2023-2024 | Ayvakit |
| Alk-Abello, INC | $70.73 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $44.19 | 2025 | Neffy |
| Mylan Specialty L.P. | $43.19 | 2021-2024 | Yupelri |
| Optinose US, INC. | $33.68 | 2019-2020 | |
| Leo Pharma INC. | $32.95 | 2022-2023 | Adbry |
| Incyte Corporation | $28.53 | 2025 | Opzelura |
| Cycle Pharmaceuticals INC | $28.30 | 2025 | Sajazir |
| Aimmune Therapeutics, INC. | $22.39 | 2021 | |
| Verona Pharma, INC. | $21.68 | 2025 | Ohtuvayre |
| Aytu Biopharma, INC. | $14.93 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.45 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Detorres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.